Moderna, with ‘Phase 3 Cancer Vaccine Success,’ Expands mRNA Oncology Domain with Monotherapy and Invivo CARTISORT

조선일보

Lean Right

Factuality

Ownership

U.S. pharmaceutical company Moderna is expanding its scope of anticancer drug development following the successful completion of Phase 3 clinical trials for its personalized messenger ribonucleic acid (mRNA) cancer vaccine. While evaluating the potential of the vaccine as a monotherapy beyond combination therapy with immunotherapies, the company is expected to broaden its research scope to include "in vivo chimeric antigen receptor T-cells (CAR-…